SCLP Scancell Holdings Plc

TIDMSCLP

RNS Number : 9791W

Scancell Holdings Plc

21 April 2023

21 April 2023

Scancell Holdings plc

("Scancell" or the "Company")

Issue of share options to Non-Executive Directors

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces that on 20 April 2023 it has granted share options to acquire ordinary shares of 0.1 pence each in the capital of the Company to the following non-executive directors:

                      Dr Jean-Michel Cosséry                 3,000,000 
                      Susan Clement Davies                  1,000,000 

These share options have an exercise price of 17.5 pence each, the closing share price as at 19 April 2023, and will vest over three years in three equal tranches from 20 April 2023 with no vesting criteria other than to remain in employment. Any unexercised share options which are being granted per the above will expire at 6pm on 20 April 2033.

The Board of Scancell approved the issuance of these share option grants to incentivise and retain Directors of the Company. The Board considered both historical practices and on-going funding requirements in this regard.

Related Party Transaction

The issue of share options to Dr. Jean-Michel Cosséry and Susan Clement Davies are deemed to be related party transactions pursuant to AIM Rule 13 of the AIM Rules for Companies. The Company's directors who are independent of the related party transactions (being all the directors other than Dr. Jean-Michel Cosséry and Susan Clement Davies) consider, having consulted with the Company's Nominated Adviser, Stifel Nicolaus Europe Limited, that the terms of the related party transactions are fair and reasonable insofar as the shareholders of the Company are concerned.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING

MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 
       Details of the person discharging managerial responsibilities/person 
   1    closely associated 
 a)    Name                             Jean-Michel Cosséry 
      -------------------------------  -------------------------------------------- 
       Reason for the notification 
  2 
      ----------------------------------------------------------------------------- 
 a)    Position/status                  Chairman of Board and PDMR 
      -------------------------------  -------------------------------------------- 
 b)    Initial notification/Amendment   Initial notification 
      -------------------------------  -------------------------------------------- 
       Details of the issuer, emission allowance market participant, 
  3     auction platform, auctioneer or auction monitor 
      ----------------------------------------------------------------------------- 
 a)    Name                             Scancell Holdings plc 
      -------------------------------  -------------------------------------------- 
 b)    LEI                              2138008RXEG856SNP666 
      -------------------------------  -------------------------------------------- 
       Details of the transaction(s): section to be repeated for (i) 
  4     each type of instrument; (ii) each type of transaction; (iii) 
        each date; and (iv) each place where transactions have been 
        conducted 
      ----------------------------------------------------------------------------- 
 a)    Description of the               Options to acquire ordinary shares 
        financial instrument, 
        type of instrument 
      -------------------------------  -------------------------------------------- 
 b)    Identification Code              GB00B63D3314 
      -------------------------------  -------------------------------------------- 
 c)    Nature of the transaction        Grant of options to acquire ordinary shares 
      -------------------------------  -------------------------------------------- 
 
 d)    Price(s) and volume(s)           3,000,000 share options 
                                         17.5 pence per share option 
      -------------------------------  -------------------------------------------- 
 e)    Aggregated information 
        - Aggregated volume               N/A (single transaction) 
        - Price 
      -------------------------------  -------------------------------------------- 
 f)    Date of the transaction          20 April 2023 
      -------------------------------  -------------------------------------------- 
 g)    Place of the transaction         Outside a trading venue 
      -------------------------------  -------------------------------------------- 
 
 
       Details of the person discharging managerial responsibilities/person 
   1    closely associated 
 a)    Name                             Susan Clement Davies 
      -------------------------------  -------------------------------------------- 
       Reason for the notification 
  2 
      ----------------------------------------------------------------------------- 
 a)    Position/status                  Non- Executive Director and PDMR 
      -------------------------------  -------------------------------------------- 
 b)    Initial notification/Amendment   Initial notification 
      -------------------------------  -------------------------------------------- 
       Details of the issuer, emission allowance market participant, 
  3     auction platform, auctioneer or auction monitor 
      ----------------------------------------------------------------------------- 
 a)    Name                             Scancell Holdings plc 
      -------------------------------  -------------------------------------------- 
 b)    LEI                              2138008RXEG856SNP666 
      -------------------------------  -------------------------------------------- 
       Details of the transaction(s): section to be repeated for (i) 
  4     each type of instrument; (ii) each type of transaction; (iii) 
        each date; and (iv) each place where transactions have been 
        conducted 
      ----------------------------------------------------------------------------- 
 a)    Description of the               Options to acquire ordinary shares 
        financial instrument, 
        type of instrument 
      -------------------------------  -------------------------------------------- 
 b)    Identification Code              GB00B63D3314 
      -------------------------------  -------------------------------------------- 
 c)    Nature of the transaction        Grant of options to acquire ordinary shares 
      -------------------------------  -------------------------------------------- 
 
 d)    Price(s) and volume(s)           1,000,000 share options 
                                         17.5 pence per share option 
      -------------------------------  -------------------------------------------- 
 e)    Aggregated information 
        - Aggregated volume               N/A (single transaction) 
        - Price 
      -------------------------------  -------------------------------------------- 
 f)    Date of the transaction          20 April 2023 
      -------------------------------  -------------------------------------------- 
 g)    Place of the transaction         Outside a trading venue 
      -------------------------------  -------------------------------------------- 
 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR)

 
 For further information, please contact: 
 
 Scancell Holdings plc                                    +44 (0) 20 3727 1000 
 Dr Jean-Michel Cosséry, Non-Executive 
  Chairman 
 Professor Lindy Durrant, CEO 
 
 Stifel Nicolaus Europe Limited (Nominated 
  Adviser and Joint Broker)                               +44 (0) 20 7710 7600 
 Nicholas Moore/ Samira Essebiyea/William Palmer-Brown 
  (Healthcare Investment Banking) 
 Nick Adams/Nick Harland (Corporate Broking) 
 
 Panmure Gordon (UK) Limited (Joint Broker)               +44 (0) 20 7886 2500 
 Freddy Crossley/Emma Earl (Corporate Finance) 
 Rupert Dearden (Corporate Broking) 
 
 FTI Consulting                                           +44 (0) 20 3727 1000 
 Simon Conway/Rob Winder/Alex Davis 
 

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope (R) and ImmunoBody (R) for vaccines and GlyMab(R) and AvidiMab (R) for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope (R) and ImmunoBody (R) ) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab(R) ) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab (R) ).

For further information about Scancell, please visit: https://www.scancell.co.uk/

, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHNKKBNOBKDDQB

(END) Dow Jones Newswires

April 21, 2023 02:00 ET (06:00 GMT)